Literature DB >> 20679238

Mnk earmarks eIF4E for cancer therapy.

Nissim Hay1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20679238      PMCID： PMC2922518          DOI： 10.1073/pnas.1008908107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  13 in total

1.  eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression.

Authors:  Luc Furic; Liwei Rong; Ola Larsson; Ismaël Hervé Koumakpayi; Kaori Yoshida; Andrea Brueschke; Emmanuel Petroulakis; Nathaniel Robichaud; Michael Pollak; Louis A Gaboury; Pier Paolo Pandolfi; Fred Saad; Nahum Sonenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

2.  mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs.

Authors:  Ryan J O Dowling; Ivan Topisirovic; Tommy Alain; Michael Bidinosti; Bruno D Fonseca; Emmanuel Petroulakis; Xiaoshan Wang; Ola Larsson; Anand Selvaraj; Yi Liu; Sara C Kozma; George Thomas; Nahum Sonenberg
Journal:  Science       Date:  2010-05-28       Impact factor: 47.728

Review 3.  The two TORCs and Akt.

Authors:  Prashanth T Bhaskar; Nissim Hay
Journal:  Dev Cell       Date:  2007-04       Impact factor: 12.270

Review 4.  eIF4E, the mRNA cap-binding protein: from basic discovery to translational research.

Authors:  Nahum Sonenberg
Journal:  Biochem Cell Biol       Date:  2008-04       Impact factor: 3.626

5.  Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development.

Authors:  Takeshi Ueda; Masato Sasaki; Andrew J Elia; Iok In Christine Chio; Koichi Hamada; Rikiro Fukunaga; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

6.  Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner.

Authors:  Jennifer E Skeen; Prashanth T Bhaskar; Chia-Chen Chen; William S Chen; Xiao-ding Peng; Veronique Nogueira; Annett Hahn-Windgassen; Hiroaki Kiyokawa; Nissim Hay
Journal:  Cancer Cell       Date:  2006-10       Impact factor: 31.743

Review 7.  Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E.

Authors:  Biljana Culjkovic; Ivan Topisirovic; Katherine L B Borden
Journal:  Cell Cycle       Date:  2007-01-11       Impact factor: 4.534

8.  mTORC1 hyperactivity inhibits serum deprivation-induced apoptosis via increased hexokinase II and GLUT1 expression, sustained Mcl-1 expression, and glycogen synthase kinase 3beta inhibition.

Authors:  Prashanth T Bhaskar; Veronique Nogueira; Krushna C Patra; Sang-Min Jeon; Youngkyu Park; R Brooks Robey; Nissim Hay
Journal:  Mol Cell Biol       Date:  2009-07-20       Impact factor: 4.272

9.  Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E.

Authors:  S Pyronnet; H Imataka; A C Gingras; R Fukunaga; T Hunter; N Sonenberg
Journal:  EMBO J       Date:  1999-01-04       Impact factor: 11.598

10.  Dissecting eIF4E action in tumorigenesis.

Authors:  Hans-Guido Wendel; Ricardo L A Silva; Abba Malina; John R Mills; Hong Zhu; Takeshi Ueda; Rie Watanabe-Fukunaga; Rikiro Fukunaga; Julie Teruya-Feldstein; Jerry Pelletier; Scott W Lowe
Journal:  Genes Dev       Date:  2007-11-30       Impact factor: 11.361
View more
  26 in total

1.  Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer.

Authors:  S Hou; P Du; P Wang; C Wang; P Liu; H Liu
Journal:  Clin Transl Oncol       Date:  2017-03-22       Impact factor: 3.405

2.  Insights into the Importance of DFD-Motif and Insertion I1 in Stabilizing the DFD-Out Conformation of Mnk2 Kinase.

Authors:  Jinqiang Hou; Theodosia Teo; Matthew J Sykes; Shudong Wang
Journal:  ACS Med Chem Lett       Date:  2013-06-24       Impact factor: 4.345

3.  Elevated levels of p-Mnk1, p-eIF4E and p-p70S6K proteins are associated with tumor recurrence and poor prognosis in astrocytomas.

Authors:  Weibing Fan; Weiyuan Wang; Xinfa Mao; Shuzhou Chu; Juan Feng; Desheng Xiao; Jianhua Zhou; Songqing Fan
Journal:  J Neurooncol       Date:  2016-11-29       Impact factor: 4.130

4.  The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance.

Authors:  Bao Hoang; Angelica Benavides; Yijiang Shi; Yonghui Yang; Patrick Frost; Joseph Gera; Alan Lichtenstein
Journal:  J Biol Chem       Date:  2012-05-03       Impact factor: 5.157

5.  IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.

Authors:  Salah-Eddine Lamhamedi-Cherradi; Brian A Menegaz; Vandhana Ramamoorthy; Deeksha Vishwamitra; Ying Wang; Rebecca L Maywald; Adriana S Buford; Izabela Fokt; Stanislaw Skora; Jing Wang; Aung Naing; Alexander J Lazar; Eric M Rohren; Najat C Daw; Vivek Subbiah; Robert S Benjamin; Ravin Ratan; Waldemar Priebe; Antonios G Mikos; Hesham M Amin; Joseph A Ludwig
Journal:  J Natl Cancer Inst       Date:  2016-08-30       Impact factor: 13.506

6.  TGFβ-induced PI 3 kinase-dependent Mnk-1 activation is necessary for Ser-209 phosphorylation of eIF4E and mesangial cell hypertrophy.

Authors:  Falguni Das; Nandini Ghosh-Choudhury; Amit Bera; Balakuntalam S Kasinath; Goutam Ghosh Choudhury
Journal:  J Cell Physiol       Date:  2013-07       Impact factor: 6.384

7.  Galeterone and VNPT55 disrupt Mnk-eIF4E to inhibit prostate cancer cell migration and invasion.

Authors:  Andrew K Kwegyir-Afful; Robert D Bruno; Puranik Purushottamachar; Francis N Murigi; Vincent C O Njar
Journal:  FEBS J       Date:  2016-10-01       Impact factor: 5.542

8.  Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.

Authors:  Sharon Lim; Tzuen Yih Saw; Min Zhang; Matthew R Janes; Kassoum Nacro; Jeffrey Hill; An Qi Lim; Chia-Tien Chang; David A Fruman; David A Rizzieri; Soo Yong Tan; Hung Fan; Charles T H Chuah; S Tiong Ong
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-04       Impact factor: 11.205

9.  Interleukin-10 inhibits lipopolysaccharide-induced tumor necrosis factor-α translation through a SHIP1-dependent pathway.

Authors:  Catherine S Chan; Andrew Ming-Lum; Gary B Golds; Shaina J Lee; Raymond J Anderson; Alice L-F Mui
Journal:  J Biol Chem       Date:  2012-09-06       Impact factor: 5.157

10.  Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.

Authors:  Ashkan Emadi; Bandish Kapadia; Dominique Bollino; Binny Bhandary; Maria R Baer; Sandrine Niyongere; Erin T Strovel; Hannah Kaizer; Elizabeth Chang; Eun Yong Choi; Xinrong Ma; Kayla M Tighe; Brandon Carter-Cooper; Blake S Moses; Curt I Civin; Anup Mahurkar; Amol C Shetty; Ronald B Gartenhaus; Farin Kamangar; Rena G Lapidus
Journal:  Leukemia       Date:  2020-11-16       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.